Compare SOLAI Limited (SLAI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SOLAI Limited vs Viatris Inc — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 1143.8× SOLAI Limited's market cap, and Viatris Inc pays a 2.89% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| SLAI | VTRS | |
|---|---|---|
Market Cap | $16.69M | $19.09B |
Sector | Technology | Health |
52-Week High | $21.63 | $17.86 |
52-Week Low | $2.74 | $9.49 |
Enterprise Value | $16.33M | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement, showing technical bullish signals despite fundamental challenges. The company reported negative financial metrics including -$33.88M net income and -134.63% net margin for 2025, though it beat Q2 2025 EPS expectations. Recent corporate actions include a 7:1 reverse stock split effective July 2026 and a NYSE delisting notice, creating significant uncertainty for investors.
The outlook remains highly speculative with substantial operational risks offset by low valuation multiples. Investment opportunity exists only for risk-tolerant investors betting on the AI infrastructure turnaround, while delisting proceedings and persistent losses present severe downside risks requiring careful monitoring of corporate developments.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
